TruScreen Group (TRU) H1 2025 earnings summary

Executive summary

• Product sales rose 5% year-over-year to $1.03 million for the six months ended 30 September 2024, with China as the main driver and strong market expansion in Vietnam, Indonesia, Uzbekistan, and Mexico.

• Operating loss narrowed to $1.13 million from $1.35 million in the prior year period.

• Net operating cash outflow reduced to $0.9 million from $1.4 million year-over-year; cash balance at period end was $1.7 million.

• Major market developments include entry into Indonesia, MOU for a 5-year screening program in Ho Chi Minh City, and ongoing validation in Uzbekistan.

• Increased recognition by WHO and inclusion in global screening guidelines, with new publications supporting product efficacy.

Financial highlights

• Revenue from product sales was $1,034,128, up from $984,512 year-over-year.

• Operating loss for the period was $1,133,478, improved from $1,356,367 in the prior year.

• Net cash outflow from operating activities was $919,839, down from $1,400,869 year-over-year.

• Cash and cash equivalents at 30 September 2024 were $1,742,167, up from $807,228 a year earlier.

• Basic and diluted loss per share was 0.21 cents, compared to 0.32 cents in the prior year.

Outlook and guidance

• Revenue growth expected to accelerate as new market entries convert to sales.

• Directors plan to raise additional capital to support expansion and move toward profitability.

• Board considers cash flow and working capital management critical for strategy execution.

• Adoption of technology anticipated to increase with recent regulatory approvals and inclusion in global guidelines.

• Commercial sales in Indonesia and Uzbekistan expected to begin in Q1 CY2025.